



[www.MedChemExpress.com](http://www.MedChemExpress.com)

Inhibitors, Screening Libraries, Proteins

# Ligands for E3 Ligase











## E3 ligase-recruiting Moiety

A PROTAC (Proteolysis Targeting Chimeric Molecule) is a protein degrader comprised of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand for target protein (target binder). The association between an E3 ligase and a target protein induced by a PROTAC will lead to the transfer of ubiquitin and degradation of the targeted protein.

E3 ligases catalyze the transfer of ubiquitin to targeted proteins and determine the specificity of the proteins. There are hundreds of E3 ligases in cells, but only a limited number of them are successfully used in reported PROTACs, such as VHL (von Hippel-Lindau disease tumor suppressor protein), CRBN (Cereblon), MDM2 (the mouse double minute 2 homologue) and IAP (inhibitor of apoptosis).

## Ligands for E3 Ligase Inhibitors, Modulators & Chemicals


<p><b>(4R,5S)-Nutlin carboxylic acid</b> (MDM2 ligand 2; E3 ligase Ligand 15)</p> <p>Cat. No.: HY-128836</p>	<p><b>(R)-Pomalidomide-pyrrolidine</b></p> <p>Cat. No.: HY-132944</p>
<p>(4R,5S)-Nutlin carboxylic acid (MDM2 ligand 2) is the Nutlin 3-based MDM2 ligand. (4R,5S)-Nutlin carboxylic acid can be connected to the ligand for protein by a linker to form PROTACs.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 g, 2 g</p>	<p>(R)-Pomalidomide-pyrrolidine, a CRBN ligand, can be connected to the ligand for protein by a linker to form PROTACs.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>(S,R,S)-AHPC</b> (VH032-NH2; VHL ligand 1)</p> <p>Cat. No.: HY-125845</p>	<p><b>(S,R,S)-AHPC hydrochloride</b> (VH032-NH2 hydrochloride; VHL ligand 1 hydrochloride)</p> <p>Cat. No.: HY-101763A</p>
<p>(S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475).</p> <p><b>Purity:</b> 98.92% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 50 mg, 100 mg</p>	<p>(S,R,S)-AHPC hydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC hydrochloride can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475).</p> <p><b>Purity:</b> 99.54% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 100 mg, 500 mg, 1 g, 5 g</p>
<p><b>(S,R,S)-AHPC TFA</b> (VH032-NH2 TFA; VHL ligand 1 TFA)</p> <p>Cat. No.: HY-110402</p>	<p><b>(S,R,S)-AHPC-Boc</b> (VH032-Boc)</p> <p>Cat. No.: HY-123109</p>
<p>(S,R,S)-AHPC TFA (VH032-NH2 TFA) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC TFA can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>(S,R,S)-AHPC-Boc (VH032-Boc) is a ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Boc is used in PROTAC technology.</p> <p><b>Purity:</b> 95.15% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 100 mg</p>
<p><b>(S,R,S)-AHPC-Me</b> (VHL ligand 2; E3 ligase Ligand 1A)</p> <p>Cat. No.: HY-112078</p>	<p><b>(S,R,S)-AHPC-Me dihydrochloride</b> (VHL ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride)</p> <p>Cat. No.: HY-42424A</p>
<p>(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Lindau (VHL) E3 ligase-based BET PROTAC degrader.</p> <p><b>Purity:</b> 98.70% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 100 mg, 500 mg</p>	<p>(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.</p> <p><b>Purity:</b> 98.39% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g</p>
<p><b>(S,R,S)-AHPC-Me hydrochloride</b> (VHL ligand 2 hydrochloride; E3 ligase Ligand 1)</p> <p>Cat. No.: HY-42424</p>	<p><b>(S,R,S)-AHPC-propargyl</b> (VH032-propargyl; VHL ligand 7)</p> <p>Cat. No.: HY-126456</p>
<p>(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.</p> <p><b>Purity:</b> 98.58% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 500 mg, 2 g</p>	<p>(S,R,S)-AHPC-propargyl (VH032-propargyl) is a VHL ligand which is used in "click reaction" for PROTACs.</p> <p><b>Purity:</b> 98.12% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 10 mg, 25 mg, 50 mg</p>

<p><b>(S,S,S)-AHPC hydrochloride</b> (S,S,S)-VH032-NH2 hydrochloride</p> <p>Cat. No.: HY-125845A</p>	<p><b>AR antagonist 1</b></p> <p>Cat. No.: HY-130845</p>
<p>(S,S,S)-AHPC hydrochloride is a von Hippel-Lindau (VHL) amino building block. (S,S,S)-AHPC (Compound 27) is a ligand used as a negative control for (S,R,S)-AHPC. (S,R,S)-AHPC is the VH032-based VHL ligand used in the recruitment of the VHL protein.</p> <p></p> <p><b>Purity:</b> 99.90% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 50 mg, 100 mg</p>	<p>AR antagonist 1 (compound 29) is a potent <b>androgen receptor (AR)</b> antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020).</p> <p></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>BC-1215</b></p> <p>Cat. No.: HY-117937</p>	<p><b>Bestatin-amido-Me</b> (PROTAC IAP binding moiety 1)</p> <p>Cat. No.: HY-111850</p>
<p>BC-1215 is an inhibitor of <b>F-box protein 3 (FBXO3)</b>, a ubiquitin E3 ligase component, <math>IC_{50}=0.9</math> <math>\mu</math>g/mL for IL-1<math>\beta</math> release). BC-1215 decreases Fbxo3-Fbxl2 interaction and prevents SCF<sup>Fbxo3</sup> catalyzed Fbxl2 ubiquitination.</p> <p></p> <p><b>Purity:</b> 99.93% <b>Clinical Data:</b> <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Bestatin-amido-Me, the Bestatin-based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.</p> <p></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>CC-17369</b> (7-Hydroxy pomalidomide; Pomalidomide metabolite M16)</p> <p>Cat. No.: HY-123215</p>	<p><b>CC-885</b></p> <p>Cat. No.: HY-101488</p>
<p>CC-17369 (7-Hydroxy pomalidomide) is a metabolite of Pomalidomide. CC-17369 is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. CC-17369 can be connected to the ligand for protein by a linker to form PROTAC.</p> <p></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>CC-885 is a cereblon (CRBN) modulator with potent anti-tumour activity.</p> <p></p> <p><b>Purity:</b> 99.23% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Cereblon inhibitor 1</b></p> <p>Cat. No.: HY-143715</p>	<p><b>CFT7455</b></p> <p>Cat. No.: HY-144841</p>
<p>Cereblon inhibitor 1, an isoindoline derivative, is a cereblon E3 ubiquitin ligase modulating drug. Cereblon inhibitor 1 has the potential for cancer research.</p> <p></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>CFT7455 is an orally active <b>zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3)</b> degrader. CFT7455 is an anti-cancer agent that binds with high affinity to the cereblon E3 ligase (<math>K_d</math> of 0.9 nM) (WO2022032132A1; Compound 1).</p> <p></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>cIAP1 ligand 1</b> (E3 ligase Ligand 12)</p> <p>Cat. No.: HY-128808</p>	<p><b>cIAP1 ligand 2</b> (E3 ligase Ligand 11)</p> <p>Cat. No.: HY-128809</p>
<p>cIAP1 ligand 1 is the LCL161 derivative based IAP ligand. cIAP1 ligand 1 can be connected to the ABL ligand for protein by a linker to form SNIPER.</p> <p></p> <p><b>Purity:</b> 98.51% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 25 mg, 50 mg, 100 mg, 250 mg</p>	<p>cIAP1 ligand 2 is the LCL161 derivative based IAP ligand. cIAP1 ligand 2 can be connected to the ABL ligand for protein by a linker to form SNIPER.</p> <p></p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 g, 2 g</p>

### cIAP1 ligand 4

Cat. No.: HY-139656

cIAP1 ligand 4 is a ligand for E3 ligase that can be used in the synthesis of PROTACs.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### CRBN modulator-1

Cat. No.: HY-138040

CRBN modulator-1, a Thalidomide analog and a CRBN modulator extracted from WO2020006262A1, compound 10, has an  $IC_{50}$  of 3.5  $\mu$ M and a  $K_i$  of 0.98  $\mu$ M.




**Purity:** 98.06%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### E3 ligase Ligand 10

Cat. No.: HY-128807

E3 ligase Ligand 10 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 10 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 g, 2 g

### E3 ligase Ligand 13

Cat. No.: HY-128810

E3 ligase Ligand 13 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 13 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 g, 2 g

### E3 ligase Ligand 14

Cat. No.: HY-128811

E3 ligase Ligand 14 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 14 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 g, 2 g

### E3 ligase Ligand 18

Cat. No.: HY-129653

E3 ligase Ligand 18 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 18 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### E3 ligase Ligand 21

Cat. No.: HY-144980

E3 ligase Ligand 21 (compound 2) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### E3 ligase Ligand 22

Cat. No.: HY-144983

E3 ligase Ligand 22 (compound 139) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### E3 ligase Ligand 23

Cat. No.: HY-144985

E3 ligase Ligand 23 (compound 17-6) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### E3 ligase Ligand 8

Cat. No.: HY-43961

E3 ligase Ligand 8 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 8 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.




**Purity:** 99.32%  
**Clinical Data:** No Development Reported  
**Size:** 25 mg, 50 mg, 100 mg, 500 mg, 1 g, 2 g

<p><b>E3 ligase Ligand 9</b></p> <p>Cat. No.: HY-128806</p>	<p><b>Eragidomide</b> (CC-90009)</p> <p>Cat. No.: HY-130800</p>
<p>E3 ligase Ligand 9 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 9 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERS. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 g, 2 g</p>	<p>Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4<sup>CRBN</sup> to selectively target GSPT1 for ubiquitination and proteasomal degradation.</p> <p><b>Purity:</b> 99.65%</p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Iberdomide</b> (CC-220)</p> <p>Cat. No.: HY-101291</p>	<p><b>KB02-COOH</b></p> <p>Cat. No.: HY-131385</p>
<p>Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC<sub>50</sub> of ~150nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities.</p> <p><b>Purity:</b> 98.84%</p> <p><b>Clinical Data:</b> Phase 3</p> <p><b>Size:</b> 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>KB02-COOH is a fragment of synthesis of ubiquitin E3 ligase ligand KB02. KB02 can be used in the synthesis of PROTAC, such as KB02-JQ1 (HY-129917) and KB02-SLF (HY-129610).</p> <p><b>Purity:</b> 98.88%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p><b>LCL-PEG3-N3</b></p> <p>Cat. No.: HY-139999</p>	<p><b>LCL-PEG3-N3 hydrochloride</b></p> <p>Cat. No.: HY-139999A</p>
<p>LCL-PEG3-N3 is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>LCL-PEG3-N3 (hydrochloride) is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Lenalidomide</b> (CC-5013)</p> <p>Cat. No.: HY-A0003</p>	<p><b>Lenalidomide hemihydrate</b> (CC-5013 hemihydrate)</p> <p>Cat. No.: HY-A0003B</p>
<p>Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.</p> <p><b>Purity:</b> 99.91%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 100 mg, 500 mg, 1 g</p>	<p>Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator.</p> <p><b>Purity:</b> 99.95%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 100 mg, 500 mg</p>
<p><b>Lenalidomide hydrochloride</b> (CC-5013 hydrochloride)</p> <p>Cat. No.: HY-A0003A</p>	<p><b>Lenalidomide-4-aminomethyl</b></p> <p>Cat. No.: HY-138882</p>
<p>Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Lenalidomide-4-aminomethyl is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-4-aminomethyl can be connected to the ligand for protein by a linker to form PROTAC.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>

### Lenalidomide-4-aminomethyl hydrochloride

Cat. No.: HY-138882A

Lenalidomide-4-aminomethyl hydrochloride is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-4-aminomethyl hydrochloride can be connected to the ligand for protein by a linker to form PROTAC.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Lenalidomide-4-OH

Cat. No.: HY-W076696

Lenalidomide-4-OH is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-4-OH can be connected to the ligand for protein by a linker to form PROTAC.




**Purity:** 98.57%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg

### Lenalidomide-5-aminomethyl

Cat. No.: HY-W077589A

Lenalidomide-5-aminomethyl is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-5-aminomethyl can be connected to the ligand for protein by a linker to form PROTAC.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Lenalidomide-5-aminomethyl hydrochloride

Cat. No.: HY-W077589

Lenalidomide-5-aminomethyl hydrochloride is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-5-aminomethyl hydrochloride can be connected to the ligand for protein by a linker to form PROTAC.




**Purity:** 98.12%  
**Clinical Data:** No Development Reported  
**Size:** 50 mg, 100 mg

### Lenalidomide-5-Br

Cat. No.: HY-W072954

Lenalidomide-5-Br is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-5-Br can be connected to the ligand for protein by a linker to form PROTAC.




**Purity:** ≥97.0%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg

### Lenalidomide-6-F

Cat. No.: HY-138881

Lenalidomide-6-F is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-6-F can be connected to the ligand for protein by a linker to form PROTAC.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Lenalidomide-Br

Cat. No.: HY-43722

Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein.




**Purity:** 99.86%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg, 250 mg, 500 mg

### Lenalidomide-d5

(CC-5013-d5)

Cat. No.: HY-A0003S

Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Lenalidomide-I

Cat. No.: HY-131318

Lenalidomide-I (Compound 72), an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, is used in the recruitment of CRBN protein.




**Purity:** 98.82%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg, 500 mg











### Lenalidomide-OH











Cat. No.: HY-133144

Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BTK degrader SJF620 (HY-133137).













**Purity:** 99.48%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 100 mg, 500 mg

<p><b>MV-1-NH-Me</b> (PROTAC IAP binding moiety 2)</p>	<p><b>N-Boc-SBP-0636457-OH</b></p>
<p>MV-1-NH-Me, the MV-1 based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>N-Boc-SBP-0636457-OH, a ligand for E3 ubiquitin ligase, is used in the recruitment of IAP E3 ligases. N-Boc-SBP-0636457-OH can be connected to the ligand for Bcl-xL by a linker to form PROTAC Bcl-xL degrader-1 (HY-131188).</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Nutlin carboxylic acid</b> (MDM2 ligand 1; E3 ligase Ligand 16)</p>	<p><b>NV03</b></p>
<p>Nutlin carboxylic acid (MDM2 ligand 1) is the Nutlin 3-based MDM2 ligand. Nutlin carboxylic acid (MDM2 ligand 1) can be connected to the ligand for protein by a linker to form PROTACs.</p>  <p><b>Purity:</b> 98.29% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>NV03 is a potent and selective antagonist of UHRF1 (Ubiquitin-like with PHD and RING finger domains 1)- H3K9me3 interaction by binding to UHRF1 tandem tudor domain, with a <math>K_d</math> of 2.4 <math>\mu</math>M. NV03 has anticancer activity.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Pomalidomide</b> (CC-4047)</p>	<p><b>Pomalidomide-5-O-CH3</b></p>
<p>Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p>  <p><b>Purity:</b> 99.96% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p>	<p>Pomalidomide-5-O-CH3 is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-O-CH3 can be connected to the ligand for protein by a linker to form PROTAC.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Pomalidomide-5-OH</b> (5-Hydroxy pomalidomide; CC-17368)</p>	<p><b>Pomalidomide-6-O-CH3</b></p>
<p>Pomalidomide-5-OH (5-hydroxy pomalidomide) is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTAC.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Pomalidomide-6-O-CH3 is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-6-O-CH3 can be connected to the ligand for protein by a linker to form PROTAC.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Pomalidomide-6-OH</b></p>	<p><b>Pomalidomide-C5-Dovitinib</b></p>
<p>Pomalidomide-6-OH is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-6-OH can be connected to the ligand for protein by a linker to form PROTAC.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

<p><b>Pomalidomide-d3</b> (CC-4047-d3)</p> <p>Pomalidomide-d3 (CC-4047-d3) is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-1098451</p> 	<p><b>Pomalidomide-d5</b> (CC-4047-d5)</p> <p>Pomalidomide-d5 is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-109845</p> 
<p><b>Pomalidomide-PEG4-COOH</b></p> <p>Pomalidomide-PEG4-COOH is a E3 ligase ligand-linker conjugate. Pomalidomide-PEG4-COOH contains the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology (extracted from patent WO2017184995A1).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 100 mg</p>	<p><b>Cat. No.:</b> HY-133699</p> 	<p><b>TD-106</b></p> <p>TD-106 is a cereblon (CRBN) modulator, which can be used for targeted protein degradation. BRD4 PROTACs with TD-106 induce BRD4 degradation.</p> <p><b>Purity:</b> 99.17% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>Cat. No.:</b> HY-114406</p> 
<p><b>Thalidomide 4-fluoride</b> (Cereblon ligand 4; E3 ligase Ligand 4)</p> <p>Thalidomide 4-fluoride (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1 (HY-129966).</p> <p><b>Purity:</b> 99.54% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mg, 50 mg, 100 mg, 500 mg</p>	<p><b>Cat. No.:</b> HY-41547</p> 	<p><b>Thalidomide 5-fluoride</b></p> <p>Thalidomide 5-fluoride is Thalidomide-based cereblon ligand that incorporates to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.</p> <p><b>Purity:</b> 99.85% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 100 mg, 250 mg, 500 mg</p>	<p><b>Cat. No.:</b> HY-W087383</p> 
<p><b>Thalidomide D4</b></p> <p>Thalidomide D4 is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the <b>cullin-4 E3 ubiquitin ligase</b> complex CUL4-RBX1-DDB1, with a <math>K_d</math> of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.</p> <p><b>Purity:</b> 98.03% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p><b>Cat. No.:</b> HY-146585</p> 	<p><b>Thalidomide-4-C3-NH2 hydrochloride</b></p> <p>Thalidomide-4-C3-NH2 hydrochloride is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-4-C3-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTACs.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-139545</p> 
<p><b>Thalidomide-4-OH</b> (Cereblon ligand 2; E3 ligase Ligand 2)</p> <p>Thalidomide-4-OH (Cereblon ligand 2) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-4-OH (Cereblon ligand 2) can be connected to the ligand for protein by a linker to form PROTACs.</p> <p><b>Purity:</b> 99.88% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 100 mg, 500 mg</p>	<p><b>Cat. No.:</b> HY-103596</p> 	<p><b>Thalidomide-5,6-Cl</b></p> <p>Thalidomide-5,6-Cl is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5,6-Cl can be connected to the ligand for protein by a linker to form PROTACs.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cat. No.:</b> HY-139547</p> 




<p><b>Thalidomide-5,6-F</b></p> <p style="text-align: right;">Cat. No.: HY-W093272</p>	<p><b>Thalidomide-5-CH2-NH2 hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-W129872</p>
<p>Thalidomide-5,6-F is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5,6-F can be connected to the ligand for protein by a linker to form PROTACs.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 50 mg, 100 mg, 500 mg</p>	<p>Thalidomide-5-CH2-NH2 (hydrochloride) is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-CH2-NH2 (hydrochloride) can be connected to the ligand for protein by a linker to form PROTACs.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Thalidomide-5-COOH</b></p> <p style="text-align: right;">Cat. No.: HY-139539</p>	<p><b>Thalidomide-5-methyl</b></p> <p style="text-align: right;">Cat. No.: HY-139548</p>
<p>Thalidomide-5-COOH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-COOH can be connected to the ligand for protein by a linker to form PROTACs.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>Thalidomide-5-methyl is the Thalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Thalidomide-5-NH2-CH2-COOH</b></p> <p style="text-align: right;">Cat. No.: HY-46531</p>	<p><b>Thalidomide-5-OH</b></p> <p style="text-align: right;">Cat. No.: HY-23095</p>
<p>Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (trk). Thalidomide-5-NH2-CH2-COOH is a ligand of E3 ligase.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> 96.03%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-5-OH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTACs.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> 98.07%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 100 mg, 250 mg, 500 mg</p>
<p><b>Thalidomide-5-PEG2-Cl</b></p> <p style="text-align: right;">Cat. No.: HY-139543</p>	<p><b>Thalidomide-5-propargyne-NH2 hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-139546</p>
<p>Thalidomide-5-PEG2-Cl is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-PEG2-Cl can be connected to the ligand for protein by a linker to form PROTACs.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>Thalidomide-5-propargyne-NH2 hydrochloride is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-propargyne-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTACs.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Thalidomide-5-propoxyethanamine</b></p> <p style="text-align: right;">Cat. No.: HY-139544</p>	<p><b>Thalidomide-benzo</b></p> <p style="text-align: right;">Cat. No.: HY-139549</p>
<p>Thalidomide-5-propoxyethanamine is the Thalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>Thalidomide-benzo hydrochloride is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-benzo can be connected to the ligand for protein by a linker to form PROTACs.</p> <div style="text-align: center;">  </div> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>

### Thalidomide-NH-CH<sub>2</sub>-COOH

Cat. No.: HY-131717

Thalidomide-NH-CH<sub>2</sub>-COOH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-NH-CH<sub>2</sub>-COOH can be connected to the ligand for protein by a linker to form PROTACs, such as THAL-SNS-032 (HY-123937).




**Purity:** 98.20%  
**Clinical Data:** No Development Reported  
**Size:** 250 mg, 500 mg

### Thalidomide-O-C8-Boc

Cat. No.: HY-131159

Thalidomide-O-C8-Boc is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-C8-Boc can be connected to the ligand for protein by a linker to form PROTACs.




**Purity:** 95.12%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 250 mg, 500 mg

### Thalidomide-O-C8-COOH

Cat. No.: HY-130952

Thalidomide-O-C8-COOH is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-C8-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs.




**Purity:** 95.30%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg, 500 mg

### Thalidomide-O-COOH

(Cereblon ligand 3; E3 ligase Ligand 3)

Cat. No.: HY-103597

Thalidomide-O-COOH (Cereblon ligand 3) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs.




**Purity:** 99.73%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg, 500 mg, 1 g, 2 g

### Thalidomide-propargyl

Cat. No.: HY-126457

Thalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-propargyl can be connected to the ligand for protein by a linker to form the IMiD containing PROTACs.




**Purity:** 99.97%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

### VH-298

Cat. No.: HY-100947

VH-298 is a highly potent inhibitor of the VHL:HIF- $\alpha$  interaction with a  $K_d$  value of 80 to 90 nM, used in PROTAC technology.




**Purity:** 99.83%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

### VH032

Cat. No.: HY-120217

VH032 is a VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. VH032 is a VHL:HIF-1 $\alpha$  interaction inhibitor with a  $K_d$  <math>/b> of 185 nM. VH032 can be connected to the ligand for protein by a linker to form PROTACs..




**Purity:** 99.52%  
**Clinical Data:** No Development Reported  
**Size:** 25 mg, 50 mg, 100 mg

### VH032 thiol

(VHL ligand 6)

Cat. No.: HY-111823

VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC.




**Purity:** 95.91%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### VH032-cyclopropane-F

(VHL ligand 3; E3 ligase Ligand 19)

Cat. No.: HY-125905

VH032-cyclopropane-F is the VH032-based VHL ligand. VH032-cyclopropane-F can be connected to the ligand for protein (e.g., SMARCA BD ligand) by a linker to form PROTACs (e.g., PROTAC 1). PROTAC 1 is a partial degrader of SMARCA2 and SMARCA4.




**Purity:** 99.39%  
**Clinical Data:** No Development Reported  
**Size:** 50 mg, 250 mg

### VH032-OH

Cat. No.: HY-136164

VH032-OH is the VH032-based VHL ligand. VH032-OH can be connected to the ligand for protein by a linker to form PROTACs.




**Purity:** 97.82%  
**Clinical Data:** No Development Reported  
**Size:** 25 mg, 50 mg

### VHL Ligand 8

Cat. No.: HY-133045

VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader.




**Purity:** 98.12%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg

### VL285

Cat. No.: HY-111663

VL285 is a potent VHL ligand with an  $IC_{50}$  of 0.34  $\mu$ M.




**Purity:** 98.84%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### $\beta$ -Naphthoflavone-CH2-Br

( $\beta$ -NF-CH2-Br)

Cat. No.: HY-130842

$\beta$ -Naphthoflavone-CH2-Br ( $\beta$ -NF-CH2-Br) is an arylhydrocarbon receptor (AhR) ligand.  $\beta$ -Naphthoflavone-CH2-Br can be used to synthesize the PROTAC  $\beta$ -NF-JQ1(HY-130256).




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### $\beta$ -Naphthoflavone-CH2-OH

( $\beta$ -NF-CH2-OH)

Cat. No.: HY-130269

$\beta$ -Naphthoflavone-CH2-OH ( $\beta$ -NF-CH2-OH) is a ligand for arylhydrocarbon receptor (AhR) E3 ligase.  $\beta$ -Naphthoflavone-CH2-OH can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs (e.g.



**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg